Duvelisib is taken orally, usually in the form of capsules. It is important to follow the doctor’s instructions for taking the medication properly:

1. Take With Food: Duvelisib should be taken twice daily with food to improve absorption and reduce potential stomach irritation.
   
   
2. Swallow the Capsules Whole: Do not crush or chew the capsules. Swallow them whole with a glass of water.
   
   
3. Consistency: Take Duvelisib at the same times every day to help remember. This will help maintain a steady level of the medication in your body.
   
   

Missed Dose: If you miss a dose of Duvelisib, take it as soon as you remember, unless it’s almost time for your next dose. In that case, skip the missed dose. Do not take two doses at once to make up for a missed dose.

Duvelisib targets and inhibits the activity of two forms of the PI3K enzyme: PI3K-delta and PI3K-gamma. These enzymes play a key role in the signaling pathways that control the survival, growth, and movement of cancer cells, particularly in blood cancers like CLL and FL. By inhibiting these enzymes, Duvelisib slows down the growth of cancer cells and may even lead to their death.

In chronic lymphocytic leukemia (CLL), these enzymes are overactive and contribute to the cancerous B cells’ survival. By blocking the activity of PI3K-delta, Duvelisib can disrupt the survival signals that keep cancerous B cells alive, thereby reducing the number of cancer cells in the blood.

In follicular lymphoma (FL), which is a type of non-Hodgkin lymphoma, Duvelisib targets the lymphoma cells, preventing their growth and spread by disrupting the pathways they rely on.

As with any medication, Duvelisib can cause side effects. It’s important to be aware of both the common and serious side effects. Some of the potential side effects include:

• Common Side Effects:
  
  
  • Diarrhea: One of the most common side effects, which can sometimes be severe.
    
    
  • Fatigue: Many patients experience tiredness or weakness while on Duvelisib.
    
    
  • Nausea and vomiting.
    
    
  • Fever or chills.
    
    
  • Decreased appetite.
    
    
• Serious Side Effects:
  
  
  • Infections: Because Duvelisib suppresses the immune system, there is an increased risk of infections (bacterial, viral, or fungal).
    
    
  • Liver Problems: Duvelisib can cause liver toxicity, leading to symptoms like jaundice (yellowing of the skin or eyes), dark urine, or abdominal pain.
    
    
  • Blood Problems: Duvelisib can affect blood counts, leading to low white blood cells, low red blood cells, or low platelets, which can increase the risk of infections, anemia, and bleeding.
    
    
  • Pneumonitis: A rare but serious lung condition that can cause shortness of breath, cough, or chest pain.
    
    

If you experience any serious side effects, contact your doctor immediately.

7. Warnings and Precautions

Before taking Duvelisib, it’s essential to consider the following warnings and precautions:

• Infections: Duvelisib suppresses the immune system, increasing the risk of serious infections. You should avoid contact with people who are sick and inform your doctor if you develop signs of an infection, such as a fever, chills, or a sore throat.
  
  
• Liver Function: Duvelisib can affect liver function, so regular liver tests are necessary during treatment. If you experience symptoms of liver problems (such as jaundice or abdominal pain), tell your doctor immediately.
  
  
• Blood Cell Counts: Duvelisib can reduce the number of certain blood cells, so regular blood tests will be needed to monitor your blood cell counts throughout treatment.
  
  
• Pneumonitis: If you experience shortness of breath or a persistent cough, inform your doctor, as this could be a sign of pneumonitis.
  
  

Pregnancy and Breastfeeding: Duvelisib is not recommended during pregnancy because it could harm an unborn baby. It is also not recommended for breastfeeding, as it could pass into breast milk.

Duvelisib can interact with several medications. Some important interactions include:

• CYP3A4 Inhibitors/Inducers: Duvelisib is metabolized by the CYP3A4 enzyme in the liver. Drugs that inhibit or induce this enzyme can affect Duvelisib levels in the body. For example, medications like ketoconazole (an antifungal) or clarithromycin (an antibiotic) can increase Duvelisib levels, while rifampin (an antibiotic) or phenytoin (an anticonvulsant) can decrease Duvelisib levels.
  
  
• Anticoagulants: Duvelisib may increase the risk of bleeding when used with blood-thinning medications (anticoagulants) such as warfarin. It is important to closely monitor for signs of bleeding.
  
  

Immunosuppressive Drugs: Since Duvelisib can suppress the immune system, using it with other immunosuppressive drugs can increase the risk of infections.

The recommended dose of Duvelisib is typically 25 mg twice daily for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients who have not responded to previous treatments. The doctor may adjust the dosage based on how well the patient responds to the medication and whether they experience side effects.

• Starting Dose: 25 mg twice a day.
  
  

Adjustments: The doctor may lower the dose or temporarily stop the medication if the patient experiences severe side effects, especially concerning liver function or blood cell counts.

Duvelisib is a prescription-only medication and can only be obtained with a doctor’s prescription. A healthcare provider will assess the patient’s medical history, previous treatments, and the type of cancer being treated before prescribing Duvelisib.

Regular monitoring, including blood tests and liver function tests, is essential during treatment to ensure the medication is working effectively and to detect any potential side effects early.

• What is Duvelisib?
  Duvelisib is a prescription medicine used to treat certain types of blood cancers, including chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL).

• How does Duvelisib work?
  It works by blocking PI3K-delta and PI3K-gamma enzymes, which help cancer cells grow and survive.

• What conditions is Duvelisib approved to treat?
  It is approved for chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and relapsed/refractory follicular lymphoma.

• What is the dosage form of Duvelisib?
  It is available as oral capsules.

• How is Duvelisib taken?
  Typically, it is taken by mouth twice daily with or without food, as prescribed by a doctor.

• Can Duvelisib be used as a first-line treatment?
  No, it is usually prescribed after at least two prior therapies have been tried.

• What are the common side effects of Duvelisib?
  Diarrhea, fatigue, cough, nausea, rash, fever, and low blood cell counts.

• What serious risks are associated with Duvelisib?
  It can cause severe infections, colitis, liver toxicity, lung inflammation, and severe skin reactions.

• Does Duvelisib suppress the immune system?
  Yes, it can weaken the immune system and increase infection risk.

• Is regular monitoring required while taking Duvelisib?
  Yes, frequent blood tests and check-ups are necessary to monitor for side effects.

• Can pregnant women take Duvelisib?
  No, it is not recommended during pregnancy because it may harm the unborn baby.

• Can breastfeeding mothers take Duvelisib?
  Breastfeeding is not recommended during treatment and for some time after the last dose.

• Does Duvelisib interact with other medications?
  Yes, especially with drugs that affect the liver enzyme CYP3A4 (like certain antibiotics, antifungals, and antivirals).

• Is Duvelisib chemotherapy or targeted therapy?
  It is a targeted therapy, specifically a PI3K inhibitor.

• How long does treatment with Duvelisib last?
  It continues until disease progression or unacceptable side effects occur.

• Is Duvelisib effective for all patients?
  Not always; its effectiveness depends on cancer type, stage, and individual patient response.

• What should I avoid while taking Duvelisib?
  Avoid grapefruit products and strong CYP3A4 inhibitors/inducers unless approved by your doctor.

• Can Duvelisib cure cancer?
  No, it helps control cancer but is not considered a cure.

• Is there a generic version of Duvelisib available?
  As of now, no FDA-approved generic is available.

• When should I contact my doctor while on Duvelisib?
  If you experience severe diarrhea, breathing problems, liver symptoms, or signs of infection.